TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05220007

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Humphrey visual field testing
Description: Perimetry was performed with the Humphrey Field Analyzer (Carl Zeiss Meditec Inc). Participants performed a 30-2 or a 24-2 Swedish Interactive Threshold Algorithm (SITA) standard test with stimulus size III, and standard Humphrey background luminance of 31.5 apostilbs. The participants were selected by simple random sampling to perform the HVF test with presbyopic collection lenses followed by without presbyopic collection lenses, or without presbyopic collection lenses followed by with presbyopic collection lenses. The power of presbyopic correction lens at the testing distance of 33 cm (the bowl radius) was auto-calculated according to the recommendation by the Humphrey Field Analyzer's manufacturer, depending on the current refractive error and the patient's age.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Humphrey visual field testing
Description: Perimetry was performed with the Humphrey Field Analyzer (Carl Zeiss Meditec Inc). Participants performed a 30-2 or a 24-2 Swedish Interactive Threshold Algorithm (SITA) standard test with stimulus size III, and standard Humphrey background luminance of 31.5 apostilbs. The participants were selected by simple random sampling to perform the HVF test with presbyopic collection lenses followed by without presbyopic collection lenses, or without presbyopic collection lenses followed by with presbyopic collection lenses. The power of presbyopic correction lens at the testing distance of 33 cm (the bowl radius) was auto-calculated according to the recommendation by the Humphrey Field Analyzer's manufacturer, depending on the current refractive error and the patient's age.
Study: NCT04524143

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: cervical mobilization
Description: Cervical mobilization techniques were applied in the study. Within the scope of application; rotation with traction, lateral gliding, anterior-posterior gliding with traction, bridging and stroking techniques to the paravertebral muscles were used. Mobilization were performed at grade A (mobilization in painless joint range) and grade B (continuous stretching at the end of the joint range). The mobilization were applied during 10 minutes.~At the end of study all patients were received home-based exercise tailored to each individual's needs which include stretching, strengthening, balance and gait exercise and posture exercise

Intervention type: OTHER
Group type: OTHER
Intervention: control
Description: There was no intervention in the control group during study. At the end of study all patients were received home-based exercise tailored to each individual's needs which include stretching, strengthening, balance and gait exercise and posture exercise

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: control
Description: There was no intervention in the control group during study. At the end of study all patients were received home-based exercise tailored to each individual's needs which include stretching, strengthening, balance and gait exercise and posture exercise
Study: NCT00157807

Intervention type: PROCEDURE
Group type: OTHER
Intervention: bipolar radiofrequency ablation of persistent and permanent AF
Study: NCT03607201

Intervention type: OTHER
Intervention: No intervention
Description: Routine care

Intervention type: OTHER
Intervention: No intervention
Description: Routine care
Study: NCT01031901

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Skincerity
Description: Study subjects will apply a study product containing polyvinylidene fluoride coating alone to either facial angiofibromas or cutaneous neurofibromas

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Skincerity
Description: Study subjects will apply a study product containing polyvinylidene fluoride coating alone to either facial angiofibromas or cutaneous neurofibromas

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Skincerity plus sirolimus/rapamycin
Description: Study subjects will apply a study product containing polyvinylidene fluoride coating plus 1 mg of sirolimus/rapamycin to either facial angiofibromas or cutaneous neurofibromas

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Skincerity plus sirolimus/rapamycin
Description: Study subjects will apply a study product containing polyvinylidene fluoride coating plus 1 mg of sirolimus/rapamycin to either facial angiofibromas or cutaneous neurofibromas

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Skinercity plus sirolimus/rapamycin
Description: Study subjects will apply a study product containing polyvinylidene fluoride coating plus 5 mg of sirolimus/rapamycin to either facial angiofibromas or cutaneous neurofibromas

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Skinercity plus sirolimus/rapamycin
Description: Study subjects will apply a study product containing polyvinylidene fluoride coating plus 5 mg of sirolimus/rapamycin to either facial angiofibromas or cutaneous neurofibromas
Study: NCT02540785

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: lenticule extraction
Description: Four femtosecond incisions were created in succession: the posterior surface of the refractive lenticule (spiral in), the lenticule border, the anterior surface of the refractive lenticule (spiral out), and the corneal flap in the superior region. After the suction was released, the flap was opened using a thin, blunt spatula and the free refractive lenticule was subsequently grasped with a forceps and extracted, after which the flap was repositioned carefully

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: small-incision lenticule extraction
Description: Four femtosecond incisions were created in succession: the posterior surface of the refractive lenticule (spiral in), the lenticule border, the anterior surface of the refractive lenticule (spiral out), make a small incision
Study: NCT01052402

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: H5N1 Influenza Vaccine (Whole Virion, Vero Cell-Derived, Inactivated), non-adjuvanted formulation
Description: Two vaccinations, 21 days apart, followed by a heterologous booster vaccination on Day 360

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: H5N1 Influenza Vaccine (Whole Virion, Vero Cell-Derived, Inactivated), non-adjuvanted formulation
Description: Two vaccinations, 21 days apart, followed by a heterologous booster vaccination on Day 360
Study: NCT02504437

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: BMMSCs

Intervention type: BIOLOGICAL
Group type: SHAM_COMPARATOR
Intervention: BMMSCs

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BMMSCs
Study: NCT00840008

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational intervention
Description: As per detailed protocol.
Study: NCT01207323

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEHD7945A
Description: MEHD7945A will be administered as specified in the individual arms.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEHD7945A
Description: MEHD7945A will be administered as specified in the individual arms.
Study: NCT04235101

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SYD985 + Niraparib
Description: SYD985 powder for concentrate for solution for infusion Niraparib 100 mg per hard capsule
Study: NCT03062059

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravesical 2000mg/52.6ml gemcitabine instillation
Description: Intravesical 2000mg/52.6ml gemcitabine instillation during operation to prevent intravesical recurrence after radical nephroureterectomy in upper urinary tract urothelial carcinoma

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Intravesical 52.6ml normal saline instillation after radical nephroureterectomy in upper urinary tract urothelial carcinoma
Study: NCT03533634

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Open Reduction Internal Fixation superior plate
Description: 3.5mm superior reconstruction plate

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Open Reduction Internal Fixation anteroinferior plate
Description: 3.5mm anteroinferior reconstruction plate
Study: NCT03075904

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALXN1830
Description: Administered via IV infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALXN1830
Description: Administered via IV infusion.
Study: NCT03301727

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive-Behavioural Therapy for Insomnia (CBT-I)
Description: Cognitive-Behavioural Therapy for Insomnia (CBT-I) is an evidence-based psycho-therapeutic intervention, combining cognitive and behavioural principles to provide psycho-education concerning contributing thoughts to sleep problem maintenance, and behavioural technique instruction to reduce sleep onset latency and promote effective sleep maintenance.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive-Behavioural Therapy for Insomnia (CBT-I)
Description: Cognitive-Behavioural Therapy for Insomnia (CBT-I) is an evidence-based psycho-therapeutic intervention, combining cognitive and behavioural principles to provide psycho-education concerning contributing thoughts to sleep problem maintenance, and behavioural technique instruction to reduce sleep onset latency and promote effective sleep maintenance.

Intervention type: OTHER
Group type: OTHER
Intervention: Cognitive-Behavioural Therapy for Insomnia (CBT-I)
Description: Cognitive-Behavioural Therapy for Insomnia (CBT-I) is an evidence-based psycho-therapeutic intervention, combining cognitive and behavioural principles to provide psycho-education concerning contributing thoughts to sleep problem maintenance, and behavioural technique instruction to reduce sleep onset latency and promote effective sleep maintenance.
Study: NCT04929093

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Novel dose adjustment of Alutard SQ
Description: novel dose adjustment schedule means directly reaching dose of Vial 4, 10,000 SQ

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: conventional dose adjustment of Alutard SQ
Description: conventional dose adjustment schedule means restarting from dose of Vial 1, 10 SQ

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Routine continuous cluster of Alutard SQ
Description: Patient receiving continuous cluster SCIT for DM during the same period
Study: NCT03836508

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Medium cut-off
Description: All the dialysis sessions in this arm will be performed with the medium cut-off membrane (MCO) manufactured by Baxter International Corp. membrane for three months. This membrane will exclusively be used in hemodialysis. After third month, all patients will be switched to high-flux membrane manufactured by Fresenius.~Modalities of hemodialysis : Blood flow: 300-400 mL/min; Dialysate flow: 500-800 mL/min

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Medium cut-off
Description: All the dialysis sessions in this arm will be performed with the medium cut-off membrane (MCO) manufactured by Baxter International Corp. membrane for three months. This membrane will exclusively be used in hemodialysis. After third month, all patients will be switched to high-flux membrane manufactured by Fresenius.~Modalities of hemodialysis : Blood flow: 300-400 mL/min; Dialysate flow: 500-800 mL/min

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: High-Flux
Description: All the dialysis sessions in this arm will be performed with the high-flux membrane manufactured by Fresenius for three months. This membrane will exclusively be used in hemodialysis. After third month, all patients will be switched to MCO manufactured by Baxter International Corp.~Modalities of hemodialysis : Blood flow: 300-400 mL/min; Dialysate flow: 500-800 mL/min

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: High-Flux
Description: All the dialysis sessions in this arm will be performed with the high-flux membrane manufactured by Fresenius for three months. This membrane will exclusively be used in hemodialysis. After third month, all patients will be switched to MCO manufactured by Baxter International Corp.~Modalities of hemodialysis : Blood flow: 300-400 mL/min; Dialysate flow: 500-800 mL/min
Study: NCT02294110

Intervention type: OTHER
Intervention: spinal anesthesia
Description: non diabetes mellitus
Study: NCT00988546

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Computer based template for exam documentation
Description: exam documentation performed using computer based template

Intervention type: OTHER
Group type: OTHER
Intervention: Dictation for exam documentation
Description: exam documentation performed using dictation, the standard practice
Study: NCT02024035

Intervention type: RADIATION
Intervention: Radiotherapy

Intervention type: RADIATION
Intervention: Radiotherapy

Intervention type: RADIATION
Intervention: Radiotherapy
Study: NCT02266602

Intervention type: RADIATION
Group type: OTHER
Intervention: Intraoperative Radiation Therapy
Description: Intraoperative radiation therapy at the time of partial mastectomy in early stage breast cancer
Study: NCT03195465

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dark Chocolate
Description: Dark Chocolate bars with 70% cacao and 30% organic cane sugar where 4 squares of the dark chocolate will be administered twice daily between the hours of 6 a.m. and 6 p.m. daily for four weeks.
Study: NCT03097861

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lubiprostone
Description: 24 mcg administered orally BID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lubiprostone
Description: 24 mcg administered orally BID

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 24 mcg administered orally BID
Study: NCT01382485

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: RIA harvesting group
Description: Subjects allocated to the RIA group will have the graft harvested in a standardized fashion using the technique described by Quintero et al. Briefly, the RIA device is a single-pass reamer that is connected to an aspirator and irrigator, allowing simultaneous reaming, irrigation, and aspiration of the contents of the femoral canal. RIA head size and tube length will be chosen based on preoperative templating of anteroposterior and lateral radiographs of the donor femur (a head size of 2mm larger than the inner cortical diameter at the isthmus of the femur will be selected). Fluoroscopic imaging will be used to confirm guidewire positioning and avoid eccentric reaming. Bone graft will be harvested from the central femoral canal and from each femoral condyle in 3 separate passes.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: AICBG harvesting group
Description: Iliac crest bone graft will be harvested from the anterior iliac crest through an incision beginning 2cm posterior to the anterior superior iliac spine and carried posteriorly. A window will be made in the iliac crest and a curette will subsequently be used to harvest the cancellous bone. The incision will be closed in 3 layers. The infiltration of local anaesthetic will be at the discretion of the surgeon.
Study: NCT03560258

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: p24CE1/2 pDNA vaccine
Description: 4 mg administered by one injection/electroporation

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: p24CE1/2 pDNA vaccine admixed with full-length p55^gag pDNA vaccine
Description: 2 mg p24CE1/2 pDNA admixed with 2 mg full-length p55\^gag pDNA administered by one injection/electroporation
Study: NCT03251261

Intervention type: DEVICE
Intervention: illumigene CMV assay, illumipro-10
Description: CMV assay for detection of CMV
Study: NCT03560258

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Full-length p55^gag pDNA vaccine
Description: 4 mg full-length p55\^gag pDNA vaccine administered by one injection/electroporation

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 mL placebo administered by one injection/electroporation
Study: NCT01153269

Intervention type: DRUG
Intervention: Lopinavir/Ritonavir (Kaletra)
Description: 3 capsules 2xdaily or 2 tablets 2xdaily Kaletra
Study: NCT03847467

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2'-Fucosyllactose
Description: Human milk oligosaccharide prebiotic dietary supplement

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Dextrose
Study: NCT02715817

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Virtual Rehabilitation
Description: It is the use of the NW games for rehabilitation of balance and gaite in post-stroke patients.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional therapeutic exercises
Description: It is the use of the conventional therapeutic exercises for rehabilitation of balance and gait in post-stroke patients.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual Rehabilitation and Conventional Therapeutic Exercise
Description: It is the use of the conventional exercises and of the NW for rehabilitation of balance and gait in post-stroke patients.
Study: NCT04714801

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: adipose derived mesenchymal stromal cells
Description: Intravenous infusion of cells

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: adipose derived mesenchymal stromal cells
Description: Intravenous infusion of cells

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Intravenous infusion of saline
Study: NCT04596137

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: İnfant pain management
Description: Kangaroo mother care was applied to the infants during heel prick. With kangaroo mother care, the pain of infants was reduced.
Study: NCT01021774

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Anal fistula treatment
Description: A comparison of collagen plug vs advancement flap surgery

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Anal fistula treatment
Description: A comparison of collagen plug vs advancement flap surgery
Study: NCT00810758

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04878691 3mg
Description: Oral solution, 3mg, twice weekly, 2 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04878691 6mg
Description: Oral solution, 6mg, twice weekly, 2 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04878691 9mg
Description: Oral solution, 9mg, twice weekly, 2 weeks
Study: NCT01930630

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Extraesophageal saline injection (ESI)
Description: The patients with advanced ESCC are to undergo extraesophageal injection of 15ml saline preoperatively and subsequently detected by EUS to confirm whether saline separates esophagus from adjacent organs.
Study: NCT03180671

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Deprogramer Sliding Guide
Description: Use of the intraoral device.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Deprogrammer Dawson B-Splint
Description: Use of the intraoral device.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Deprogrammer Kois
Description: Use of the intraoral device.
Study: NCT00744328

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Transdermal Estradiol
Description: Estradiol patch ranging in dose from 50 to 200 mcg/day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sertraline
Description: Sertraline dose will range from 50 - 200 mg/day

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo patches and pills that are identical to transdermal estradiol and oral sertraline, respectively, will be used.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo patches and pills that are identical to transdermal estradiol and oral sertraline, respectively, will be used.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo patches and pills that are identical to transdermal estradiol and oral sertraline, respectively, will be used.
Study: NCT04785664

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Community-based pro-Active Monitoring Program
Description: The Intervention provides phone monitoring addressed to all the clients and home visits tailored to the individual needs. Moreover, it activates other formal or informal care resources based on the needs of the patients reported in the Individualized Care Plan (ICP) which derives from the assessment of multidimensional frailty. The main peculiarity of the program is that the operators identify the main problem of the client and try to track down the best solution in agreement with the client. It can be a health or social intervention or a different kind. Interventions may include assistance to make clients' houses safer thereby reducing risk factors for falls or reviewing the therapeutic scheme to improve patient adherence to the treatment in collaboration with the GP.
Study: NCT02093676

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: experimental protocol treatment The New Authority
Study: NCT02430701

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Irreversible electroporation (IRE)
Description: Irreversible Electroportion For Unresectable Esophageal Neoplasms guide with ultrasound or/and CT.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NanoKnife
Study: NCT02428244

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing
Description: Motivational Interviewing coupled with education will be provided to help participants understand the risks associated with smoking and their fracture care. They will be referred to the quitline.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing + Follow-up
Description: Motivational Interviewing coupled with education will be provided to help participants understand the risks associated with smoking and their fracture care. They will be referred to the quitline.~In this intervention, the participants will receive additional motivational interviewing sessions at 2 weeks, 6 weeks, 3 months and 6 months.
Study: NCT04564950

Intervention type: OTHER
Intervention: Observation of serum and salivary Galectin-3 levels
Description: Observation of serum and salivary Galectin-3 levels and correlation with periodontal indices
Study: NCT02200029

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ademetionine IV+tablet
Description: IV ademetionine (500 mg/vial) for 2 weeks followed by oral ademetionine (500 mg/tablet, 2 in the morning and 1 before dinner) for 6 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ademetionine tablet
Description: oral ademetionine (500 mg/tablet, 2 in the morning and 1 before dinner) for 8 weeks
Study: NCT00655083

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nepadutant
Description: 0.1 mg/Kg as one single oral dose divided in three age strata (from 6 to 24 weeks old)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nepadutant
Description: 0.5 mg/Kg as one single oral dose divided in three age strata (from 6 to 24 weeks old)